Loading...
Projects / Programmes source: ARIS

Pharmaceutical technology: from drug delivery systems to therapeutic outcomes of medicines in children end elderly

Periods
Research activity

Code Science Field Subfield
1.09.00  Natural sciences and mathematics  Pharmacy   
3.08.00  Medical sciences  Public health (occupational safety)   

Code Science Field
B740  Biomedical sciences  Pharmacological sciences, pharmacognosy, pharmacy, toxicology 

Code Science Field
3.01  Medical and Health Sciences  Basic medicine 
3.03  Medical and Health Sciences  Health sciences 
Keywords
Pharmaceutical technology, Biopharmacy, Pharmacokinetics, Bioanalysis, Social Pharmacy, Pharmacotherapy, Subpopulations, Elderly, Children, Polypharmacotherapy, Medication Adherence, Biologicals.
Evaluation (rules)
source: COBISS
Points
16,034.36
A''
1,986.96
A'
6,336.39
A1/2
8,962.62
CI10
18,058
CImax
262
h10
61
A1
54.24
A3
20.86
Data for the last 5 years (citations for the last 10 years) on April 14, 2024; A3 for period 2018-2022
Data for ARIS tenders ( 04.04.2019 – Programme tender , archive )
Database Linked records Citations Pure citations Average pure citations
WoS  1,049  21,074  19,050  18.16 
Scopus  1,264  24,296  22,077  17.47 
Researchers (56)
no. Code Name and surname Research area Role Period No. of publicationsNo. of publications
1.  15490  PhD Pegi Ahlin Grabnar  Pharmacy  Researcher  2018 - 2023  210 
2.  54786  Ana Baumgartner  Pharmacy  Junior researcher  2020 - 2023  21 
3.  38497  PhD Maja Bjelošević Žiberna  Pharmacy  Researcher  2022 - 2023  78 
4.  11124  PhD Marija Bogataj  Pharmacy  Researcher  2018 - 2023  374 
5.  32694  PhD Katarina Bolko Seljak  Pharmacy  Researcher  2019 - 2020  55 
6.  17432  Margareta Cof    Technical associate  2018 - 2023 
7.  34096  PhD Nanča Čebron Lipovec  Pharmacy  Researcher  2021 - 2023  73 
8.  37547  PhD Andreja Detiček  Pharmacy  Junior researcher  2018  24 
9.  53585  PhD Črt Dragar  Pharmacy  Junior researcher  2019 - 2021  37 
10.  21455  PhD Rok Dreu  Pharmacy  Researcher  2018 - 2023  292 
11.  52168  Tjaša Felicijan  Pharmacy  Researcher  2023  26 
12.  18700  Valerija Garb    Technical associate  2018 - 2023 
13.  11789  PhD Mirjana Gašperlin  Pharmacy  Researcher  2018 - 2023  600 
14.  28446  PhD Ilija German Ilić  Pharmacy  Researcher  2018 - 2023  141 
15.  29887  PhD Mirjam Gosenca Matjaž  Pharmacy  Researcher  2018 - 2023  139 
16.  16107  PhD Iztok Grabnar  Pharmacy  Researcher  2018 - 2023  439 
17.  55103  Nina Katarina Grilc  Pharmacy  Researcher  2023  17 
18.  52093  PhD Andrej Grobin  Pharmacy  Junior researcher  2018 - 2023  12 
19.  29979  PhD Nejc Horvat  Pharmacy  Researcher  2019 - 2023  87 
20.  17433  Tatjana Hrovatič    Technical associate  2018 - 2023 
21.  34670  PhD Biljana Janković  Pharmacy  Researcher  2018 - 2023  137 
22.  55891  Nuša Japelj  Pharmacy  Junior researcher  2021 - 2023 
23.  34930  PhD Janja Jazbar  Pharmacy  Researcher  2021 - 2023  46 
24.  12942  PhD Janez Kerč  Pharmacy  Researcher  2018 - 2021  240 
25.  20370  PhD Mojca Kerec Kos  Pharmacy  Researcher  2018 - 2023  243 
26.  18699  Mojca Keržan    Technical associate  2018 - 2023 
27.  24402  PhD Petra Kocbek  Pharmacy  Researcher  2018 - 2021  294 
28.  35028  PhD Ana Kodrič  Pharmacy  Researcher  2022 - 2023  54 
29.  17434  Mihaela Kolarev    Technical associate  2018 - 2023 
30.  20374  PhD Mitja Kos  Pharmacy  Head  2018 - 2024  485 
31.  11122  PhD Albin Kristl  Pharmacy  Researcher  2018 - 2023  350 
32.  09032  PhD Julijana Kristl  Pharmacy  Retired researcher  2018 - 2023  932 
33.  32037  PhD Zoran Lavrič  Pharmacy  Researcher  2018 - 2023  67 
34.  17430  Nevenka Lilik    Technical associate  2018 - 2023 
35.  24399  PhD Igor Locatelli  Pharmacy  Researcher  2018 - 2023  275 
36.  39199  PhD Janja Mirtič  Pharmacy  Junior researcher  2018 - 2020  56 
37.  06086  PhD Aleš Mrhar  Pharmacy  Retired researcher  2018 - 2023  1,161 
38.  36441  PhD Urška Nabergoj Makovec  Pharmacy  Researcher  2018 - 2023  62 
39.  14935  PhD Odon Planinšek  Pharmacy  Researcher  2018 - 2023  438 
40.  37548  PhD Tanja Potrč  Pharmacy  Researcher  2022 - 2023  43 
41.  56839  Monika Prašnikar  Pharmacy  Junior researcher  2022 - 2023 
42.  56837  Nina Ravbar  Pharmacy  Junior researcher  2022 - 2023 
43.  50681  Katarina Rede  Pharmacy  Junior researcher  2019 - 2021  12 
44.  23549  PhD Robert Roškar  Pharmacy  Researcher  2018 - 2023  304 
45.  09031  PhD Stanko Srčič  Pharmacy  Retired researcher  2018 - 2023  675 
46.  34299  PhD Barbara Sterle Zorec  Pharmacy  Researcher  2018 - 2023  48 
47.  38166  PhD Žane Temova Rakuša  Pharmacy  Researcher  2018 - 2023  46 
48.  53933  Armando Tratenšek  Pharmacy  Junior researcher  2020 - 2023 
49.  23420  PhD Jurij Trontelj  Pharmacy  Researcher  2018 - 2023  258 
50.  54024  Mercedes Vitek  Pharmacy  Researcher  2023  23 
51.  18155  PhD Tomaž Vovk  Pharmacy  Researcher  2018 - 2023  231 
52.  08333  PhD Franc Vrečer  Pharmacy  Researcher  2018 - 2023  399 
53.  36439  PhD Špela Zupančič  Pharmacy  Researcher  2018 - 2023  127 
54.  26226  PhD Alenka Zvonar Pobirk  Pharmacy  Researcher  2018 - 2023  210 
55.  22659  PhD Simon Žakelj  Pharmacy  Researcher  2018 - 2023  162 
56.  50680  PhD Špela Žerovnik  Pharmacy  Junior researcher  2019 - 2021  21 
Organisations (1)
no. Code Research organisation City Registration number No. of publicationsNo. of publications
1.  0787  University of Ljubljana, Faculty of Pharmacy  Ljubljana  1626973  17,462 
Abstract
The main focus of the Programme Group “Pharmaceutical technology: from drug delivery systems to therapeutic outcomes of medicines in children and elderly” is the delivery of the active pharmaceutical ingredients (API) to the targeted site in the body and the optimization of drug therapy in different groups of patients. The Group's research programme is designed and substantiated with three pillars, originating in the knowledge of three participating departments and will be horizontally and vertically integrated. The programme content is of increasingly complexness, spanning from the development of drug delivery systems, including all aspects of their physico-chemical, technological, biological, biopharmaceutic and pharmacokinetic characterisation, to the evaluation of therapeutic outcomes after using the designed new and modified drug delivery systems, mostly in children and elderly. Multiunit and flexible dosage forms, such as granules, pellets and mini tablets will be produced. Oral films will be prepared by casting technology, electrospinning and 2D-printing. Orodispersible tablets will be prepared  by lyopillisation or direct compression. Bioadhesive polymers, which can improve drug bioavailability, will be also systematically investigated. Lipid based drug delivery systems as well as other technological approaches to solve the problem of variable (low) drug bioavailability and large presystemic metabolism will be researched. Advanced delivery systems for application of macromolecules in their biological active form will be developed as well. Release of API from formulations in vitro under physiological and pathophysiological conditions and those of special patient subpopulations will be studied. The solubility as well as supersaturation of different active substances will be investigated. Permeability, distribution and metabolism of API in different in vitro and in vivo models will be examined. In silico testing, e.g. mathematical modelling and computer simulation will be used as a support to reduce the extent of experimental work. To support multiple and diverse fields of research within our Programme Group, such as evaluation of delivery systems, studies of biopharmaceutic and pharmacokinetic processes, the therapeutic drug monitoring and screening and analysis of environmental samples, our analytical expertise will provide a state-of-the-art methodology offering a reliable identification and confident quantification of (multiple) APIs and their metabolites in various complex samples. Finnaly, clinical, humanistic and economic outcomes of pharmacotherapy will be evaluated to improve patients’ adherence, to study medication burden with concomitant alcohol use and the frailty syndrome among the elderly and to develop new approaches in medicines’ evaluation systems for healthcare decision-making, especially for new and innovative medicines.
Significance for science
The Programme group “Pharmaceutical technology: from drug delivery systems to therapeutic outcomes of medicines in children and elderly” at the Faculty of Pharmacy, University of Ljubljana includes members of three chairs: The Chair of Biopharmaceutics and Pharmacokinetics, The Chair of Pharmaceutical Technology and The Chair of Social Pharmacy and experts from Slovenian pharmaceutical industry. Wide and interdisciplinary expertise of research group enables diverse approaches to the challenges in the development of generic and biosimilar drug delivery systems, thus enabling basic and applicative scientific work on the highest level on the fields of pharmaceutical technology, biopharmacy, experimental and clinical pharmacokinetics, and social and clinical pharmacy. In the scope of the pharmaceutical technology field we will focus on patient friendly delivery systems which represent a basis of personalized pharmacotherapy and improve patient adherence during therapy. Study of drug delivery systems from the view of formulation and its production process will enable the development of multiunit and flexible dosage forms. New approaches to the production of delivery systems based on the electrospinning and electrospraying, 2D-printing and lyophilisation will be developed, thus enabling the preparation of new (nano)delivery systems and flexible formulations. Lipid based drug delivery systems, dry emulsions, self-(micro) emulsifying dosage forms and (trans)dermal delivery systems based on the colloidal associative structures of surface active substances will be studied. The results of our work will contribute to the scientific development also on the fields of nanotheranostics and nanofibres with biomolecules for tissue regeneration. The technology of layer-by-layer process of delivery systems or live cell nanoencapsulation will also be developed. The results will enable better knowledge of the structures of developed systems and the mechanisms of the processes during their preparation and after administration. The researches of the new drug delivery systems will be accompanied by studies of biopharmaceutical and pharmacokinetic processes to which the drug incorporated in these delivery systems is exposed after administration, evaluation of these processes and parallel development of advanced analytical methodology for determination of drugs and their metabolites in technological and biological samples. Mechanisms of drug release and the influences on this process will be evaluated in simulated in vivo conditions, and the different processes of supersaturation as possible mechanism of drug release will be studied also from the point of delivery system. Insight into the mechanisms of membrane transport and basic classification of permeability and distribution will be obtained using models with different levels of complexity like cell lines and ex vivo animal tissues; metabolism and distribution will also be evaluated in in vivo animal models. Primarily, the permeability through the intestinal mucosae and the distribution between the blood and the brain will be researched. The development of complex models based on different cell lines will enable concurrent evaluation of transport and metabolism where the in vitro preservation of intracellular architecture and intercellular communications will be highly relevant. The study of the described processes will be supported by the development of advanced analytical methodology. Mathematical modelling will enable additional insight into the mechanisms of different processes, also in the cases where there is limited possibility of experimentation on real systems and large variability of the results. We will develop methods for modelling the impact of concomitant variables, including the genetic factors for the purpose of evaluation of interindividual differences observed in the action of drugs, and the pharmacokinetic-pharmacodynamic models for the small molecules and for biopharmaceuticals
Significance for the country
Programme group 'Pharmaceutical technology: from drug delivery systems to therapeutic outcomes of medicines in children end elderly' represents national research center for drug development from production, through laboratory in vitro and in vivo testing to evaluation of therapeutic and pharmacoeconomic outcomes. The group develops technologic, biopharmaceutic, pharmacokinetic and pharmacosocial experises, which are complementary combined and in this manner enables successful and competetiv ability of national pharmaceutical industry. Consequently it significantly contributes and will contribute to development of better drugs and health outcomes improvement with emphasis on patients life quality. Republic of Slovenia similarly as other EU countries faces pronounced changes in population age picture moving towards more mature structure with lower percentage of workers. This influences healthcare expenditure which has reached 8,7% (2013) of Slovenian GDP and about 500 million EUR is spent for drugs every year. According to the demographic changes in Europe, the European Medicines Agency adopted Guidelines for the development of drugs for pediatric use (EMA/480235/2010) and Geriatrics medicines strategy (EMA/CHMP/137793/2011). In the frame of the proposed programme challenges appearing by the development of new drugs and different therapeutics regimens for treatment of children and eldery popuation will be solved using scientific aproaches in three pilars which are interconnected horizontally and vertically and follow the approach of growing complexity, which means from the development of delivery systems, their physico-chemical, technologic, biologic, biopharmaceutic and pharmacokinetic evaluation to therapeutic outcomes.    Knowledge which is needed in the area of development, production and use of drugs is of strategic importance also for the batchelors of pharmacy, masters of science and doctors of pharmacy who are educated at the Faculty of Pharmacy in Ljubljana. Most of them find an employment in Slovenian pharmaceutical industry and are mostly experts in pharmaceutical technology and biopharmacy. Young specialists from both fields are important factors of companies' success and regions development where drugs are produced. Similar is true also for pharmacists employed in Slovenian health care system (community pharmacists, clynical pharmacists and pharmacoinformators) who are capable of supporting optimal patient treatment in relation to expenditure for drugs. Results of proposed programme will lead to decreased use of drugs in the population with consequently positive impact on drug efectivness and safety with lower costs of patient treatment. We thus believe that the results of proposed programme will be important for Slovenian pharmaceutical industry and for Slovenian health care system.
Most important scientific results Interim report
Most important socioeconomically and culturally relevant results Interim report
Views history
Favourite